Navigation Links
Array BioPharma Announces Pricing Of Public Offering Of Common Stock
Date:11/9/2012

BOULDER, Colo., Nov. 9, 2012 /PRNewswire/ -- Array BioPharma Inc. (NasdaqGM: ARRY) announced today the pricing of an underwritten public offering of 18,000,000 primary shares of its common stock at a public offering price of $3.65 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $65.7 million. The offering is expected to close on or about November 15, 2012, subject to customary closing conditions. Array also granted the underwriters a 30-day option to purchase 2,700,000 additional shares of common stock to cover over-allotments, if any. All of the shares sold in the offering are being sold by Array, with the proceeds to be used to fund research and development activities and for general corporate purposes. Jefferies & Company, Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, with Piper Jaffray & Co., Stifel Nicolaus Weisel and William Blair acting as co-managers.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission (the "SEC") and is effective. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.  Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming part of the effective shelf registration statement.

A preliminary prospectus supplement relating to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov.  Copies of the final prospectus supplement and accompanying prospectus, when available, may be obtained from either: Jefferies & Company, Inc., Equity Syndicate Prospectus Department, at 520 Madison Avenue, New York, New York, 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by calling (866) 803-9204.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small‑molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly‑owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. 

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the completion, timing and size of the proposed offering and other statements that are other than statements of historical facts. These statements involve significant risks and uncertainties. Because these statements reflect our current expectations concerning future events, our actual events could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to: the risk that the financing may be delayed or may not occur due to market or other conditions and the satisfaction of customary closing conditions related to the proposed public offering. Additional information concerning these and other factors that may cause actual events to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of Array's most recent Annual Report on Form 10-K, in our other periodic reports and filings with the Securities and Exchange Commission and in the prospectus supplement related to the offering. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Array on the date hereof, and we undertake no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

CONTACT: Tricia Haugeto
(303) 386-1193
thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array BioPharma Announces Proposed Public Offering Of Common Stock
2. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
3. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
4. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
5. Agility Clinical Expands Consulting Services to More Broadly Serve Small and Virtual Biopharma and Device Companies
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
7. PDL BioPharma Announces Third Quarter 2012 Financial Results
8. PDL BioPharma to Announce Third Quarter 2012 Financial Results on November 5, 2012
9. New Study Highlights Enabling Factors for Biopharmaceutical Innovation in Middle-Income Countries
10. SAFC Enters South Korean BioPharma Market with CrystalGenomics Agreement
11. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017   Genprex, Inc. , a privately held, ... Pham , MD, the Company,s Chief Operating Officer, is scheduled to ... Sachs 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, ... York, NY ... BioCentury 24th Annual Future Leaders in Biotech Industry – ...
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, ... leading in vivo pharmacology contract research organization ... adjacent to its newly expanded preclinical research facility in ... farm provides a cleaner, renewable energy source to reduce ... environment. Completion of the Genesis Solar Farm follows Invivotek,s ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 Abdominal ... to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% from 2016 ... revenue, and is projected to dominate the market during the study period. ... ... Logo ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... 27, 2017 , ... Adding to its expanding portfolio of ... and NEJM Journal Watch, announces the release of NEJM Knowledge+ Pediatrics Board ... of pediatricians from leading medical centers. The content was then reviewed and approved ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... The comprehensive weight management program at Women’s Excellence will help patients lose weight ... and physical exam. The specialists at Women's Excellence will measure BMI, body ...
(Date:3/27/2017)... ... ... Schloz is still in shock after receiving a $2,500 Academic Award from California Casualty ... said. , She thinks the coming week is going to be a very joyful for ... help my students.” , The award will allow the 4th grade teacher at Tumwater Hill ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... ... has entered a settlement agreement to resolve the pending litigation between itself and ... for the District of Utah). , “I am thrilled to announce that we ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician Dr. Justin Harper ... prestigious award honoring the top influencers on RealSelf—the most trusted online destination to ... and clinics. , In 2016, more than 82 million people visited RealSelf to ...
Breaking Medicine News(10 mins):